Skip to content

Abstract 14409: Residual Risk of Ischemic Stroke Despite Anticoagulation in Patients Hospitalized with Atrial Fibrillation: Insights from the Get With The Guidelines-Atrial Fibrillation Program

Nov 2026 · Circulation · 0 citations

Abstract

Background: Oral anticoagulation (OAC) substantially reduces stroke risk in atrial fibrillation (AF), yet residual risk persists even among treated patients. Contemporary real-world data on this residual risk, its determinants, and longitudinal adherence to OAC are limited. Methods: We analyzed patients ≥65 years of age hospitalized with AF in the Get With The Guidelines-Atrial Fibrillation (GWTG-AFIB) registry, linked to Medicare claims (2017-2023), who were discharged on OAC. Patients with contraindications, without guideline indication or an alternate indication for OAC were excluded. Outcomes included ischemic stroke/systemic embolism (SE) and all-cause mortality through 3 years. Incident rates were calculated per 1000 person-years. Factors associated with stroke were assessed using cause-specific Cox models with LASSO-based variable selection. Post-discharge adherence was assessed using the proportion of days covered (PDC ≥80%) from Medicare Part D data. Results: Among 15,873 patients (mean (SD) age 76(8) years; 55.8% female), 405 (2.6%) experienced stroke/SE over 3 years (incidence 11.9 per 1000 person-years), while all-cause mortality was 28.7% (incidence 124 per 1000 person-years). Residual stroke risk increased significantly with age (>75 years: 15.7 vs 7.9 per 1000 person-years), prior stroke/TIA (23.0 vs 9.8), diabetes (15.4 vs 10.5), and GARFIELD (stroke and systemic embolism) score >2 (25.0 vs 8.9) (all p<0.001) [Table 1]. Independent predictors of stroke included age (aHR:1.22 [1.14-1.30] per 5 years), prior stroke/TIA (aHR: 1.67[1.22, 2.27]), diabetes (aHR 1.48 [1.20, 1.84]), and GARFIELD risk >2 (aHR 1.52[1.11, 2.09]). OAC adherence remained 50-55% across all 6-month intervals through 3 years, with only ~40% of patients remaining under observation at 30-36 months [Figure 1]. Conclusions: Among patients hospitalized with AF and discharged on OAC, substantial residual stroke risk persists, driven by clinical risk factors rather than treatment gaps alone. Despite guideline-directed therapy being prescribed at discharge, long-term adherence remains suboptimal. These findings highlight the need for improved risk stratification and strategies to optimize sustained anticoagulation and adjunctive therapies.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.